TheraRadar
← Back
Data updated: Jun 28, 2026

ENTASIS THERAP

Pharma
Infectious Disease Execution: Excellent

ENTASIS THERAP is a pharmaceutical company focused on Infectious Disease. Key products include XACDURO (COPACKAGED).

2023
Since
2
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
2 Small Molecules

FDA Novel Drug Designations

(2023-2025)
2 Novel 1 First-in-Class 2 Priority Review 2 Fast Track
See 2 novel approvals →
2025 NUZOLVENCE (ZOLIFLODACIN) First-in-Class · Priority Review · Fast Track
2023 XACDURO (COPACKAGED) (DURLOBACTAM SODIUM) Priority Review · Fast Track

ENTASIS THERAP at a Glance

  • Strong track record with 100% execution quality across 9 trials
  • Fast trial execution (4 months median completion)

ENTASIS THERAP's Key Drugs

ENTASIS THERAP's core commercial portfolio centers on XACDURO (COPACKAGED), NUZOLVENCE, spanning Infectious Disease — its most strategically important drugs approved in the last 15 years.

XACDURO (COPACKAGED)
Infectious Disease
Approved 2023
NUZOLVENCE
Infectious Disease
Approved 2025

ENTASIS THERAP's Recent FDA Approvals

ENTASIS THERAP secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

NUZOLVENCE NDA
2025-12-12
zoliflodacin
1 INDICATIONS AND USAGE NUZOLVENCE is a spiropyrimidinetrione bacterial type II topoisomerase inhibitor indicated for the treatment of uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae in adults and pediatric patients 12 years of age and older, weighing at least 35 kg. ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZOLVENCE and other antibacterial drugs, NUZOLVENCE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Uncomplicated Urogenital Gonorrhea NUZOLVENCE is indicated for the treatment of uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae in adults and pediatric patients 12 years of age and older, weighing at least 35 kg [see Clinical Studies (14) ]. 1.2 Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZOLVENCE and other antibacterial drugs, NUZOLVENCE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

ENTASIS THERAP's Therapeutic Areas

ENTASIS THERAP's approved drugs and pipeline span 1 therapeutic area, led by Infectious Disease, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 100%
0 drugs Phase 3: 1 Phase 2: 1 Phase 1: 4

ENTASIS THERAP's Top Competitors

ENTASIS THERAP's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Infectious Disease
Merck big-pharma
Infectious Disease
Baxter specialty
Infectious Disease
AbbVie big-pharma
Infectious Disease
Johnson & Johnson big-pharma
Infectious Disease

ENTASIS THERAP Pipeline Snapshot

ENTASIS THERAP has 6 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 1 Phase 2 and 4 Phase 1.

1
Phase 3
1
Phase 2
4
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • XACDURO (COPACKAGED) leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Infectious Disease pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 1/1 completed
  • • Speed: 4 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges